FluxSurvodutide
Dual GLP-1/glucagon agonist. Fat loss with energy.
About
What it is
Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 side suppresses appetite. The glucagon side increases energy expenditure and fat oxidation. Clinical data shows strong weight loss with particular effectiveness on liver fat.
How it works
Survodutide activates GLP-1 receptors (appetite suppression) and glucagon receptors (increased energy expenditure and fat oxidation). The glucagon component also reduces liver fat specifically.
Benefits
Who it's for
What to expect
Week 1–2
Appetite changes and increased energy expenditure begin.
Week 4–8
Weight loss accelerates. Liver fat begins decreasing.
Week 12–16
Significant body composition and metabolic improvements.
Safety & tolerability
Survodutide is in clinical trials with an emerging safety profile. The GLP-1 side effects are familiar. Glucagon activation is carefully balanced to avoid excessive blood sugar elevation. Our care team monitors metabolic markers closely.
How we compound
Single-source API
Every peptide is sourced from one vetted pharmaceutical-grade supplier — no blending from multiple sources.
Third-party tested
Independent labs verify purity, potency, sterility, and endotoxin levels before any batch is released.
Care team reviewed
A real person reviews your profile, your protocol, and your progress. Not an algorithm.
Weight Loss
FluxSurvodutide
Every protocol is reviewed by our care team before it ships. Questions? Learn more
$279/mo
You might also consider
ContourSemaglutide
The GLP-1 that changed weight management forever.
EvolveTirzepatide
Dual-action GLP-1/GIP. The next generation of weight management.
Apex-3Retatrutide
Triple agonist. Three pathways. One injection.